Indefinite Delivery Contract 75D30120D07515
Award Date
4/1/20
Last Date to Order
3/31/21
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide a range of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.26 billion, multiple-award IDC has a period of performance from April 1, 2023 through March 31, 2024. The contract aims to procure a minimum of 100 doses up to a maximum ranging from 100,000 to 13 million doses of 21 different pediatric vaccines,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide up to 23 standard pediatric vaccines. The $1.14 billion, multiple-award contract has a period of performance from April 1, 2022 to March 31, 2023 and supports pediatric immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. The vaccines, which must have a minimum...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC as the prime contractor. The contract, valued at up to $1.25 billion, is part of the Vaccines for Children (VFC) 2015 program and provides for the delivery of various vaccines and pharmaceutical products to support federal immunization and disease prevention initiatives. Key products and services included under this multiple award IDV contract include seasonal influenza...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract, valued at up to $1.489 billion, is for the procurement of standard commercial pediatric vaccines to support the Vaccines for Children (VFC) program over a 12-month period from April 1, 2025 to March 31, 2026. The solicitation was unrestricted, without any small business...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under the Vaccines for Children 2021 program to support pediatric immunization efforts. The contracts hold a potential value of $1.039 billion and were awarded to Glaxosmithkline, LLC for the period of April 1, 2021 through March 31, 2022. The contracts will provide 20 standard pediatric vaccines to the CDC's Immunization Awardees for distribution through the Vaccines for Children program and Section...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a global healthcare company and manufacturer of essential plasma-derived medicines and vaccines. The contract, valued at a ceiling of $12,409,500, is for the supply of 20 standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to support the Vaccines for Children program and Section 317(j) of the Public Health Service Act. The prime contractor is Sanofi Pasteur Inc. The contract has a potential value of $1.537 billion and a period of performance from April 1, 2021 through March 31, 2022. Under this IDV, the contractor will provide 20 standard pediatric vaccines to support immunization...